FR2714057B1
(fr)
*
|
1993-12-17 |
1996-03-08 |
Sanofi Elf |
Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
|
FR2741621B1
(fr)
*
|
1995-11-23 |
1998-02-13 |
Sanofi Sa |
Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
|
FR2742148B1
(fr)
*
|
1995-12-08 |
1999-10-22 |
Sanofi Sa |
Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2758723B1
(fr)
*
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
FR2761265B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
WO1999053917A1
(en)
|
1998-04-21 |
1999-10-28 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cannabinoids as antioxidants and neuroprotectants
|
JP3852644B2
(ja)
|
1998-09-21 |
2006-12-06 |
チッソ株式会社 |
分割型複合繊維、これを用いた不織布及び吸収性物品
|
FR2789079B3
(fr)
*
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
FR2799124B1
(fr)
*
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
FR2800372B1
(fr)
*
|
1999-11-03 |
2001-12-07 |
Sanofi Synthelabo |
Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
|
FR2804604B1
(fr)
*
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
JP2004502642A
(ja)
|
2000-02-11 |
2004-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
|
FR2809621B1
(fr)
*
|
2000-05-12 |
2002-09-06 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
US8449908B2
(en)
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
WO2003007887A2
(en)
|
2001-07-20 |
2003-01-30 |
Merck & Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
FR2831883B1
(fr)
*
|
2001-11-08 |
2004-07-23 |
Sanofi Synthelabo |
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
SE0104330D0
(sv)
*
|
2001-12-19 |
2001-12-19 |
Astrazeneca Ab |
Therapeutic agents
|
EP1490043A4
(en)
*
|
2002-03-26 |
2007-05-30 |
Merck & Co Inc |
SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
|
FR2837706A1
(fr)
*
|
2002-03-28 |
2003-10-03 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
|
JP4459629B2
(ja)
*
|
2002-04-12 |
2010-04-28 |
メルク エンド カムパニー インコーポレーテッド |
二環式アミド
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US7402835B2
(en)
*
|
2002-07-18 |
2008-07-22 |
Chevron U.S.A. Inc. |
Heteroatom-containing diamondoid transistors
|
BR0312297A
(pt)
|
2002-07-18 |
2005-04-12 |
Cytos Biotechnology Ag |
Conjugados veìculos de hapteno e seu uso
|
AU2003250117B2
(en)
|
2002-07-29 |
2007-05-10 |
F. Hoffmann-La Roche Ag |
Novel benzodioxoles
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
GB0228417D0
(en)
*
|
2002-12-05 |
2003-01-08 |
Cancer Rec Tech Ltd |
Pyrazole compounds
|
CN101012193A
(zh)
|
2003-01-02 |
2007-08-08 |
霍夫曼-拉罗奇有限公司 |
新cb 1受体反激动剂
|
PL378244A1
(pl)
|
2003-01-02 |
2006-03-20 |
F. Hoffmann-La Roche Ag |
Pirolilotiazole i ich zastosowanie jako odwrotnych agonistów receptora CB 1
|
AR043633A1
(es)
*
|
2003-03-20 |
2005-08-03 |
Schering Corp |
Ligandos de receptores de canabinoides
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
WO2004111033A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Astrazeneca Ab |
2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
MXPA05013733A
(es)
|
2003-06-20 |
2006-03-08 |
Hoffmann La Roche |
2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
AU2004299198A1
(en)
|
2003-12-08 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Novel thiazole derivates
|
FR2864958B1
(fr)
*
|
2004-01-12 |
2006-02-24 |
Sanofi Synthelabo |
Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
|
EP1574211A1
(en)
|
2004-03-09 |
2005-09-14 |
Inserm |
Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
|
BRPI0510679A
(pt)
|
2004-05-10 |
2007-12-26 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
UA88910C2
(ru)
|
2004-07-12 |
2009-12-10 |
Кадила Хелткере Лимитед |
Гетероциклические соединения для предотвращения или ослабления симптомов заболеваний, которые лечатся коноплей, и способы их получения
|
FR2873372B1
(fr)
*
|
2004-07-22 |
2006-09-08 |
Sanofi Synthelabo |
Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
FR2874012B1
(fr)
*
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
DE602005007765D1
(de)
|
2004-10-27 |
2008-08-07 |
Hoffmann La Roche |
Neue indol- oder benzimidazol-derivate
|
EP2127676A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related disorders
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
JP4675969B2
(ja)
|
2004-11-09 |
2011-04-27 |
エフ.ホフマン−ラ ロシュ アーゲー |
ジベンゾスベロン誘導体
|
RU2007122351A
(ru)
*
|
2004-11-15 |
2008-12-20 |
Тайсо Фармасьютикал Ко. |
Иминовое соединение
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
US20080234323A1
(en)
*
|
2005-01-06 |
2008-09-25 |
Braj Bhushan Lohray |
Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
AU2006203845A1
(en)
*
|
2005-01-10 |
2006-07-13 |
Alexandros Makriyannis |
Novel heteropyrrole analogs acting on cannabiniod receptors
|
FR2881744B1
(fr)
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
FR2882262B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882263B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
DE102005011050A1
(de)
|
2005-03-10 |
2006-09-21 |
Degussa Ag |
Verfahren zur Herstellung von 1-Aminopiperidinderivaten
|
CA2602787C
(en)
|
2005-04-06 |
2013-12-24 |
F. Hoffmann-La Roche Ag |
Pyridine-3-carboxamide derivatives as cb1 inverse agonists
|
CN1310891C
(zh)
*
|
2005-05-19 |
2007-04-18 |
金鑫 |
N-哌啶基-1-(2,4-二氯苯基)-4-甲基-5-(4-氯苯基)吡唑-3-甲酰胺有机酸盐及其药物组合物
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
NZ564759A
(en)
|
2005-06-30 |
2011-08-26 |
Prosidion Ltd |
GPCR agonists
|
FR2888236B1
(fr)
*
|
2005-07-08 |
2007-09-21 |
Sanofi Aventis Sa |
Derives de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique
|
EP1743637A1
(en)
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP1752149A1
(en)
|
2005-07-29 |
2007-02-14 |
Laboratorios Del Dr. Esteve, S.A. |
CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
CA2624030A1
(en)
|
2005-09-29 |
2007-04-12 |
Tianying Jian |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
JP5069894B2
(ja)
*
|
2005-10-21 |
2012-11-07 |
田辺三菱製薬株式会社 |
ピラゾール化合物
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
EP1816125A1
(en)
*
|
2006-02-02 |
2007-08-08 |
Ranbaxy Laboratories, Ltd. |
Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
|
FR2897060B1
(fr)
*
|
2006-02-08 |
2008-07-25 |
Sanofi Aventis Sa |
Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
WO2007121687A1
(fr)
*
|
2006-04-26 |
2007-11-01 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China |
Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
|
CN101062919B
(zh)
*
|
2006-04-26 |
2012-08-15 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
FR2902008A1
(fr)
*
|
2006-06-07 |
2007-12-14 |
Sanofi Aventis Sa |
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
AR061606A1
(es)
*
|
2006-06-22 |
2008-09-10 |
Medichem Sa |
Formas solidas de rimonabant y procesos para su preparacion
|
US20100204470A1
(en)
|
2006-06-27 |
2010-08-12 |
Sandoz Ag |
method for salt preparation
|
US7297710B1
(en)
|
2006-07-12 |
2007-11-20 |
Sanofi-Aventis |
Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
|
BRPI0715160A2
(pt)
|
2006-08-08 |
2013-06-11 |
Sanofi Aventis |
imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
|
WO2008026219A2
(en)
*
|
2006-09-01 |
2008-03-06 |
Hetero Drugs Limited |
Novel polymorphs of rimonabant
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008035023A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Cipla Limited |
Polymorphs of rimonabant
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
WO2008056377A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Cadila Healthcare Limited |
Polymorphic forms of rimonabant
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
WO2008064615A2
(en)
*
|
2006-12-01 |
2008-06-05 |
Zentiva, A.S. |
Crystalline and amorphous forms of rimonabant and processes for obtaining them
|
CZ300115B6
(cs)
*
|
2006-12-01 |
2009-02-11 |
Zentiva, A. S. |
Zpusob výroby N-piperidino-5-(4-chlorfenyl)-1-(2,4-dichlorfenyl)-4-methylpyrazol-3-karboxamidu (rimonabantu)
|
AR064735A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr y composicion farmaceutica en base al compuesto
|
EP2377863A1
(en)
|
2007-01-04 |
2011-10-19 |
Prosidion Limited |
Piperidine GPCR agonists
|
CL2008000017A1
(es)
|
2007-01-04 |
2008-08-01 |
Prosidion Ltd |
Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
US20100048625A1
(en)
|
2007-01-04 |
2010-02-25 |
Matthew Colin Thor Fyfe |
Piperidine gpcr agonists
|
US20080182877A1
(en)
*
|
2007-01-05 |
2008-07-31 |
Westheim Raymond J H |
Rimonabant forms and methods of making the same
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
EP1944297A1
(en)
*
|
2007-01-09 |
2008-07-16 |
Miklós Vértessy |
Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
|
EP1953144A1
(en)
*
|
2007-01-30 |
2008-08-06 |
Sandoz AG |
Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
|
WO2008102367A1
(en)
*
|
2007-02-19 |
2008-08-28 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
WO2008101860A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Sandoz Ag |
Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
|
FR2913018A1
(fr)
*
|
2007-02-23 |
2008-08-29 |
Sanofi Aventis Sa |
Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
JP4994295B2
(ja)
*
|
2007-04-20 |
2012-08-08 |
田辺三菱製薬株式会社 |
医薬組成物
|
CN101302200B
(zh)
*
|
2007-05-09 |
2011-04-20 |
上海医药工业研究院 |
制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
|
FR2919184A1
(fr)
*
|
2007-07-26 |
2009-01-30 |
Sanofi Aventis Sa |
L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
|
FR2919864A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919868A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
|
FR2919861A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919862A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919866A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de methanol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919867A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
|
FR2919863A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
FR2919865A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
WO2009109222A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Maprimed, S. A. |
Process for the preparation of rimonabant
|
WO2009153804A1
(en)
*
|
2008-06-16 |
2009-12-23 |
Cadila Healthcare Limited |
Process for preparing form i of rimonabant
|
TW201014822A
(en)
|
2008-07-09 |
2010-04-16 |
Sanofi Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
CN102482312A
(zh)
|
2009-08-26 |
2012-05-30 |
赛诺菲 |
新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
CN102206182B
(zh)
*
|
2011-04-11 |
2013-03-13 |
中国药科大学 |
盐酸利莫那班的合成方法
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
AU2012316331B2
(en)
*
|
2011-09-30 |
2016-02-25 |
National Health Research Institutes |
Pyrazole compounds
|
EP3152200A1
(en)
|
2014-06-06 |
2017-04-12 |
Research Triangle Institute |
Apelin receptor (apj) agonists and uses thereof
|
MX2018006979A
(es)
|
2015-12-09 |
2019-05-16 |
Res Triangle Inst |
Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos.
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
ES2947188T3
(es)
|
2020-11-18 |
2023-08-02 |
Fundacion Del Hospital Nac De Paraplejicos Para La Investigacion Y La Integracion Fuhnpaiin |
Uso de antagonistas y/o agonistas inversos de receptores CB1 para la preparación de medicamentos para tratar el síndrome de fatiga posviral
|